Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib

British Journal of Cancer

Volumn 89, Issue , 2003, Pages S15-S18

  Katz, A ^a   Zalewski, P ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b SCARBOROUGH HOSPITAL   (Canada)

Author keywords

Antitumour activity; Brain metastases; Egfr; Gefitinib ( Iressa zd 1839); Quality of life

Indexed keywords

GEFITINIB;

ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG TOLERANCE; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; QUINAZOLINES;

EID: 0347319031     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601478     Document Type: Article

References (21)

1. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor-tyrosine kinase inhibitor ZD1839 (‘Iressa’). Clin Cancer Res 8: 3250– 3258
2. Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, Calandri C, Bartolini S, Santoro A, Crino L (2003a) Epidermal growth factor receptor targeted therapy by ZD 1839 (‘Iressa’) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 41: 227–231
3. Cappuzzo F, Calandri C, Bartolini S, Crino L (2003b) ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 89: 246– 247
4. Ceresoli GL, Gregorc V, Cappuzzo F, Spreafico A, Bencardino KB, Lombardo L, Schipani S, Cozzarini C, Crino L, Villa E (2003) ZD1839 in non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Proc Am Soc Clin Oncol 22: 674 (abs 2709)
5. Chiu C-H, Tsai C-M, Chiang S-C, Chen Y-M, Perng R-P (2003) Effect of ZD1839 (‘Iressa’) on metastatic brain lesions in patients with advanced non-small cell lung cancer. Lung Cancer 41(Suppl 2): 251 (abs P-631)
6. Ekstrand AJ, Sugawa N, James CD, Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastoma reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89: 4309–4313
7. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M (2003) Dramatic effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 40: 73–76
8. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237– 2246
9. Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2002) Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (‘Iressa’). Clin Cancer Res 8: 3496– 3502
10. Huang SM, Li J, Armstrong EA, Harari PM (2002) Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (‘Iressa’). Cancer Res 62: 4300–4306
11. Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch Jr TJ, Penson RT (2003) Living as a cancer surpriser: a doctor tells his story. Oncologist 8: 108–122
12. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belini CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy and safety of gefitinib (‘Iressa’, ZD1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small cell lung cancer. A randomized trial. JAMA 22: 2149–2158
13. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange J-L, Milano G (2002) Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86: 819–827
14. Peery TS, Reardon DA, Quinn J, Ochs J, Wikstrand CJ, Stenzel TT, Bigner DD, Friedman HS, Rich JN, Dancey J (2003) Phase II trial of ZD1839 for patients with first relapse glioblastoma. Proc Am Soc Clin Oncol 22: 99 (abs 396)
15. Pino MS, Gelibter A, Ceribelli A, Milella M, Pollera CF, Moscetti L, Di Cocco B, Salesi N, Cognetti F (2003) Results from compassionate use of gefitinib (‘Iressa’) in progressive pretreated non small cell lung cancer (NSCLC): our experience. Lung Cancer 41(Suppl 2): 250 (abs P-627)
16. Rodrigus P, de Brouwer P, Raaymakers E (2001) Brain metastases and nonsmall cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer 32: 129–136
17. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C (2003) EGFR blockade with ZD1839 (‘Iressa’) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys 55: 713–723
18. van Vulpen M, Kal HB, Taphoorn MJB, El Sharouni SY (2002) Changes in blood–brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 9: 683– 688 (review)
19. Villano JL, Mauer AM, Vokes EE (2003) A case study documenting the anticancer activity of ZD1839 (‘Iressa’) in the brain. Ann Oncol 14: 656–658
20. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR, Bigner DD (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140–3148
21. Williams KJ, Telfer BA, Stratford IJ, Wedge SR (2002) ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86: 1157–1161